PhotoMedex (PHMD) to Release Quarterly Earnings on Wednesday
PhotoMedex (NASDAQ:PHMD) is scheduled to be issuing its quarterly earnings data on Wednesday, November 6th. Parties that are interested in participating in the company’s conference call can do so using this link.
PhotoMedex (NASDAQ:PHMD) last released its earnings data on Wednesday, August 7th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.34 by $0.22. The company had revenue of $58.10 million for the quarter, compared to the consensus estimate of $59.75 million. On average, analysts expect PhotoMedex to post $1.30 EPS for the current fiscal year and $1.43 EPS for the next fiscal year.
Shares of PhotoMedex (NASDAQ:PHMD) opened at 12.80 on Tuesday. PhotoMedex has a 52-week low of $9.85 and a 52-week high of $17.05. The stock’s 50-day moving average is $15.02 and its 200-day moving average is $15.7. The company has a market cap of $263.3 million and a price-to-earnings ratio of 9.81.
PHMD has been the subject of a number of recent research reports. Analysts at Gabelli initiated coverage on shares of PhotoMedex in a research note to investors on Friday, September 13th. They set a “buy” rating on the stock. Analysts at Canaccord Genuity raised their price target on shares of PhotoMedex from $22.00 to $25.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. PhotoMedex presently has an average rating of “Buy” and a consensus target price of $20.93.
PhotoMedex, Inc (NASDAQ:PHMD) is a Global Skin Health Solutions company that provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.